-
Mashup Score: 10
ESMO 2021 results of KEYNOTE-199, follow-up assessing pembrolizumab monotherapy for docetaxel-pretreated mCRPC, next-generation hormonal agent and docetaxel, safety profile with pembrolizumab.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
KEYNOTE-199, KEYNOTE-199 updated efficacy and safety data after an additional 1 year of follow-up, KEYNOTE-199 pembrolizumab in mCRPC
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Pembrolizumab + enzalutamide for enzalutamide-resistant #mCRPC: updated analyses after one additional year of follow-up from cohorts 4 and 5 of the #KEYNOTE199 study. Presentation by @JulieGr28180604 @OHSUKnight. #ASCO21 written coverage by @zklaassen_md > https://t.co/qFVSQOB8RO https://t.co/i8NMdQNMqK
-
-
Mashup Score: 3ASCO GU 2020: KEYNOTE-199: Pembrolizumab Plus Enzalutamide for Enzalutamide-Resistant mCRPC: Cohorts 4-5 - 4 year(s) ago
ASCO GU 2020 cohorts 4 and 5 of KEYNOTE-199, a multicohort phase II study of men with metastatic castration-resistant prostate cancer (mCRPC). Keynote 199 mCRPC.
Source: www.urotoday.comCategories: UrologyTweet
-
Mashup Score: 1ASCO GU 2020: Pembrolizumab Plus Enzalutamide for Enza-Resistant Metastatic Castration-Resistant Prostate Cancer: KEYNOTE-199 Cohorts 4-5 - 4 year(s) ago
ASCO GU 2020, Rapid Abstract Session, A: Prostate Cancer, results for KEYNOTE-199 Cohort 4 and 5, addition of pembrolizumab to enzalutamide following enzalutamide resistance showed modest antitumor activity
Source: www.urotoday.comCategories: UrologyTweet
Pembrolizumab monotherapy for docetaxel-pretreated #mCRPC. Updated analyses with 4 years of follow-up from cohorts 1-3 of #KEYNOTE199. Presentation by @EAntonarakis @hopkinskimmel. #ESMO21 written coverage by @zklaassen_md @GACancerCenter > https://t.co/SE6wDrnYBZ @myESMO https://t.co/XTt6GMbZ5A